NextGen is positioning itself to be the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers, with a focus on prostate and breast cancer. The company plans to leverage cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical companies.

Contact Information

46 Aldgate High Street
36 Spital Square
LondonEC3N 1AL,

tel: 44-0-20-7031-1189


Investor Relations



Exchange: OTCBB
Industry: Unknown
Market Cap: N/A

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.